Abstract library

201 results for "cumulative dose".
#2998 Inter- and Intrapatient Mean Absorbed Dose Variation and Simplification of Dosimetric Workflow after PRRT
Introduction: Post-PRRT dosimetry is not routinely performed, partly due to required multiple imaging time points. One time point imaging would reduce patient burden, and make dosimetry more applicable in the clinical settings.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Daphne Huizing
#2698 Safety and Efficacy of Salvage PRRT with 177Lu-DOTA-Octreotate in Patients with Well-Differentiated Metastatic Neuroendocrine Tumours (NET)
Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective therapy in patients with a somatostatin receptor-positive neuroendocrine tumour (NET). NETTER-1 trial demonstrated high efficacy and low toxicity of four cycles.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Nariman Ghaleb
#101 Chronic Complications of Peptide Receptor Radionuclide Therapy (PRRT)- A Single Center Experience
Introduction: In the last decade, a new treatment modality, peptide receptor radionuclide therapy (PPRT), has been introduced for gastroenteropancreatic neuroendocrine tumor (GEPNET) patients with non-resectable or progressive disease. PRRT has been associated with several complications, including bone marrow suppression, renal toxicity and hepatic damage.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Merav Fraenkel
#320 Predictors of Clinical Response to Everolimus in Patients with Well-differentiated Metastatic Pancreatic NETs
Introduction: Everolimus (E) is an mTOR inhibitor with promising antitumor activity in patients with NETs. Predictor factors of response could improve the clinical use of this compound.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Maria Cristina De Martino
#781 Effect of Mean Absorbed Renal Dose on the Renal Function After Peptide Receptor Radionuclide Therapy
Introduction: Kidneys are the critical organs in peptide receptor radionuclide therapy (PRRNT) of neuroendocrine neoplasms (NENs).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr. Harshad Kulkarni
#840 Clinical Impact of Everolimus Cumulative Dose on Pancreatic Neuroendocrine Tumors (pNETs) Outcome
Introduction: Everolimus is approved for advanced pancreatic neuroendocrine tumors (pNETs).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: Rossana Berardi
#900 Renal Effects of Streptozocin: Preliminary Results of the STREPTOTOX Study
Introduction: Based on old studies, Streptozocin (STZ) is known to have some renal toxicity.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Emmanuel Mitry
#1155 Evaluation of Features and Predictors for Long Term Hematologic Toxicity in Neuroendocrine Patients Treated with Peptide Receptor Radionuclide Therapy
Introduction: Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET) may offer partial or complete objective response in up to 30% of patients. To deliver treatment in a safe and effective manner, long term adverse events should be considered.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Suzanne Richter
Keywords: PRRT
#1388 Nephrotoxicity after PRRT with 177Lu-DOTA-Octreotate
Introduction: Renal toxicity may occur after Peptide Receptor Radionuclide Therapy (PRRT). Risk factors have been identified for renal toxicity after 90Y based PRRT.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Hendrik Bergsma
#1534 Personalized 177Lu-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) Allows a Safe and Significant Increase of Radiation Dose to Neuroendocrine Tumors (NETs)
Introduction: 177Lu-octreotate PRRT is commonly administered at fixed/empiric activity per cycle, which results in highly variable radiation doses to critical organs and undertreatment of the majority of patients.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Michela Del Prete